The primary objective of the study is to evaluate the safety of AT2101.

The secondary objective of the study is to assess pharmacodynamic effects of AT2101, including beta-glucocerebrosidase (GCase), glucocerebroside (GlcCer), chitotriosidase, and pulmonary and activation regulated chemokine (PARC).

32

All

18 Years to 65 Years (Adult)

NCT00433147

GAU-CL-201

February 2007

February 2008

March 2008

February 9, 2007

August 19, 2010

University of California San FranciscoSan Francisco, California, United States

University Research Foundation for Lysosomal Storage Diseases, IncCoral Springs, Florida, United States

Emory University Lysosomal Storage Disease CenterDecatur, Georgia, United States